摘要
目的:探讨帕立骨化醇对维持性血液透析患者继发性甲状旁腺功能亢进和微炎症状态治疗效果评价。方法:选择2018年1月至2021年1月于我院血液净化中心常规透析合并继发性甲状旁腺功能亢进患者84例为研究对象,按照随机数字表法,随机分为对照组和研究组,各42例;其中对照组患者采用骨化三醇口服治疗;研究组患者采用帕立骨化醇治疗,均治疗8周。对治疗前后2组患者的全段甲状旁腺激素(iPTH)、血磷、血钙、C反应蛋白(CRP)水平以及骨钙素N端中分子片段(N-MID)、β-胶原降解产物(β-CTX)和总Ⅰ型胶原氨基端延长肽(tPINP)等骨代谢指标进行分析、比较。结果:治疗后2组的iPTH、血磷和CRP水平均较治疗前显著下降,而血钙水平显著高于同组治疗前(P<0.05);且研究组与对照组上述指标比较差异有统计学意义(P<0.05)。研究组N-MID、β-CTX和tPINP等骨代谢指标比对照组明显降低(P<0.05)。结论:应用帕立骨化醇能够有效降低继发性甲状旁腺功能亢进血液透析患者iPTH水平,抑制CRP表达,改善骨代谢产物,疗效相比骨化三醇可能更有效。
Objective:To explore the therapeutic effects of paricalcitol on secondary hyperparathyroidisim and micro-inflammatory state in maintenance hemodialysis patients.Methods:A total of 84 hemodialysis patients with secondary hyperparathyroidisim treated in our hospital from Jan 2018 to Jan 2021 were randomly selected and divided into two groups,42 cases in each group.The control group was treated with calcitriol,and the study group was treated with paricalcitol.Both were treated for 8 weeks.The levels of iPTH,serum phosphorus,serum calcium,CRP,N-MID,β-CTX and tPINP were compared.Resuls:The levels of iPTH,serum phosphorus and CRP decreased and serum calcium increased significantly in the two groups after treatment(P<0.05),which was more evident in the study group(P<0.05).Compared with the control group,the bone metabolic markers N-MID,β-CTX and tPINP decreased significantly in the study group after treatment(P<0.05).Conclusions:The application of paricalcitol in the hemodialysis patients with secondary hyperparathyroidisim can reduce the levels of iPTH,CRP and bone metabolic markers.Compared with calcitriol,paricalcitol plays a more effective role.
作者
刘勇
谈雅吟
童昌军
LIU Yong;TAN Yayin;TONG Changjun(Department of Blood Purification Centre,Yijishan Hospital,Wannan Medical College,Wuhu 241001,China)
出处
《沈阳医学院学报》
2022年第3期263-266,共4页
Journal of Shenyang Medical College
基金
芜湖市科技计划项目(No.2020rkx4-4)。
作者简介
刘勇,E-mail:236853400@qq.com;通信作者:谈雅吟,E-mail:48484643@qq.com。
